Table 3

Multivariable rate ratios and 95% CIs predicting new episodes (n-121) of anti-TNF use

IRR*CI
Age (5 years)0.77(0.68 to 0.88)
1.04(0.71 to 1.54)
Medicaid coverage0.34(0.18 to 0.66)
Region
 Midwest1.00(Reference)
 Northeast1.17(0.69 to 1.97)
 Southeast1.29(0.80 to 2.07)
 Southwest1.13(0.57 to 2.22)
 Rocky Mountains0.61(0.14 to 2.63)
 Pacific and HI, AK, PR0.99(0.49 to 2.01)
Urban/suburban0.89(0.60 to 1.34)
Systemic corticosteroids (oral)
 Short course2.35(1.59 to 3.47)
 Maintenance therapy2.40(1.05 to 5.48)
Non-biological immunomodulators3.35(2.10 to 5.35)
Aminosalicylates2.03(1.37 to 3.02)
Locally administered steroids3.80(1.90 to 7.61)
Antidiarrhoeals0.67(0.33 to 1.33)
Hospitalisations1.18(1.01 to 1.38)
Endoscopy (>1)0.97(0.43 to 2.23)
IBD-associated surgery1.09(0.14 to 8.52)
  • *Poisson regression with time-to-event as time offset, incident anti-TNF use as dependent variable.

  • AK, Alaska; HI, Hawaii; IBD, inflammatory bowel disease; IRR, incidence rate ratios; PR, Puerto Rico; TNF, tumour necrosis factor.